Showing 27 companies
6K’s UniMelt® microwave plasma develops advanced materials across a wide spectrum of markets including additive manufacturing and battery storage. It’s positioned to replace today’s traditional processes, which are environmentally unfriendly. 6K overcomes these limitations, delivering a significantly lower cost, more sustainable approach. In additive manufacturing, the UniMelt utilizes materials like CNC scrap and turns it into premium powder. With close to 100% yield, energy is saved and waste eliminated throughout the process. Competing technologies create 70-75% scrap and are forced to either send it to landfill or put it back into the supply chain, increasing energy and carbon waste dramatically.
Anzu Partners is a venture capital and private equity firm that invests in breakthrough industrial technologies. We team with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations.
Aspinity is revolutionizing the design of battery-operated, always-on sensing devices. The company's unique analog machine learning processor introduces a completely new, bio-inspired approach to always-on sensing that improves battery life by 10x by eliminating the power-wasting processing of irrelevant data. Headquartered in Pittsburgh, Aspinity delivers the power- and data-efficient solution required for the next generation of portable always-on devices for IoT, smart home, consumer, industrial, and medical applications such as voice/sound wake-up, industrial machine health monitoring, and wearable health monitoring.
Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity in both the research and clinical space studies using our proprietary genome amplification system. Bioskryb’s SkrybAmp technology enables even coverage of the entire genome during DNA amplification and allows for unparalleled accuracy and uniformity in DNA sequence coverage and base calling. We believe our technology will enable a new generation of single cell and low DNA input genomics applications in diverse markets like cancer genomics, bacterial genomics, personal genomics and Minimal Residual Disease testing.
Codetta™ Bioscience is a venture-backed company with a razor-sharp focus on solving some of the biggest problems in the life sciences and healthcare industries. We are developing life science research and medical diagnostics tools with state-of-the-art performance metrics to address severe disease states including cancer, heart, and Alzheimer’s disease. Our technology empowers significant advances in this field by enabling broad coverage of protein and genetic biomarkers at low cost in high-throughput or point-of-need formats.
With over fifteen years of experience, Edge is a world-class designer and manufacturer of custom, micro-featured, thermoplastic disposables for diagnostic, medical, and optical applications. Whether you have ready-to-manufacture product specifications or need product development and/or design for manufacturing (DFM) support, Edge can significantly reduce risk and time-to-market with our scalable, rapid design validation and precision manufacturing platform.
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.